Imunon announces press release available

Imunon, Inc.

Imunon, Inc.

IMNN

0.00
  • Imunon released a July 23, 2026 announcement on new IMNN-001 data set for presentation at AACR D3 in Boston, July 21-24.
  • Poster highlights Phase 2 OVATION-2 results: median overall survival 40.5 months vs. 27.6 months with chemotherapy alone; final results cited 45.1 vs. 30.4.
  • Update also points to a rapidly recruiting Phase 3 OVATION-3 trial, positioned as pivotal for a potential BLA filing if successful.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230925PRIMZONEFULLFEED9766830) on July 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.